Literature DB >> 3110147

A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor.

P A Foster, C A Fulcher, T Marti, K Titani, T S Zimmerman.   

Abstract

We have identified a Factor VIII (FVIII) binding domain residing within the amino-terminal 272 amino acid residues of the mature von Willebrand Factor (vWF) subunit. Two-dimensional crossed immunoelectrophoresis showed direct binding of purified human FVIII to purified human vWF. After proteolytic digestion of vWF with Staphylococcus aureus V8 protease (SP), FVIII binding was seen only with the amino-terminal SP fragment III and not with the carboxyl-terminal SP fragment II. A monoclonal anti-vWF antibody (C3) partially blocked FVIII binding to vWF and SP fragment III. FVIII also bound to vWF which had been adsorbed to polystyrene beads. This binding was inhibited in a dose-dependent manner by whole vWF, SP fragment III, and by monoclonal antibody C3. Binding could not be inhibited by SP fragment I, which contains the middle portion of the vWF molecule, or by reduced and alkylated whole vWF. SP fragment II caused only minimal inhibition. Trypsin cleavage of SP fragment III produced a monomeric 35-kDa fragment containing the amino-terminal 272 amino acid residues of vWF. This fragment reacted with monoclonal antibody C3 and inhibited the binding of FVIII to vWF in a dose-dependent manner. These studies demonstrate that a major FVIII binding site resides within the amino-terminal 272 amino acid residues of vWF.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3110147

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

Review 1.  Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technology.

Authors:  R J Kaufman
Journal:  Ann Hematol       Date:  1991-09       Impact factor: 3.673

2.  A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in mice.

Authors:  Andrew Yee; Robert D Gildersleeve; Shufang Gu; Colin A Kretz; Beth M McGee; Keisha M Carr; Steven W Pipe; David Ginsburg
Journal:  Blood       Date:  2014-05-21       Impact factor: 22.113

3.  Identification of amino acid residues responsible for von Willebrand factor binding to sulfatide by charged-to-alanine-scanning mutagenesis.

Authors:  Takayuki Nakayama; Tadashi Matsushita; Koji Yamamoto; Noriko Mutsuga; Tetsuhito Kojima; Akira Katsumi; Norihiko Nakao; J Evan Sadler; Tomoki Naoe; Hidehiko Saito
Journal:  Int J Hematol       Date:  2008-05       Impact factor: 2.490

4.  Visualization of an N-terminal fragment of von Willebrand factor in complex with factor VIII.

Authors:  Andrew Yee; Austin N Oleskie; Anne M Dosey; Colin A Kretz; Robert D Gildersleeve; Somnath Dutta; Min Su; David Ginsburg; Georgios Skiniotis
Journal:  Blood       Date:  2015-06-11       Impact factor: 22.113

Review 5.  Laboratory diagnosis of von Willebrand disease.

Authors:  J C Roberts; V H Flood
Journal:  Int J Lab Hematol       Date:  2015-05       Impact factor: 2.877

6.  A common ancestor more than 10,000 years old for patients with R854Q-related type 2N von Willebrand's disease in Italy.

Authors:  Alessandra Casonato; Viviana Daidone; Giovanni Barbon; Elena Pontara; Irene Di Pasquale; Lisa Gallinaro; Letizia Marullo; Giorgio Bertorelle
Journal:  Haematologica       Date:  2012-08-08       Impact factor: 9.941

Review 7.  Molecular genetics of type 2 von Willebrand disease.

Authors:  Edith Fressinaud; Claudine Mazurier; Dominique Meyer
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

8.  A monoclonal antibody to von Willebrand factor (vWF) inhibits factor VIII binding. Localization of its antigenic determinant to a nonadecapeptide at the amino terminus of the mature vWF polypeptide.

Authors:  W F Bahou; D Ginsburg; R Sikkink; R Litwiller; D N Fass
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

9.  Identification and characterization of the elusive mutation causing the historical von Willebrand Disease type IIC Miami.

Authors:  T Obser; M Ledford-Kraemer; F Oyen; M A Brehm; C V Denis; R Marschalek; R R Montgomery; J E Sadler; S Schneppenheim; U Budde; R Schneppenheim
Journal:  J Thromb Haemost       Date:  2016-08-20       Impact factor: 5.824

10.  The pro-polypeptide of von Willebrand factor is required for the formation of a functional factor VIII-binding site on mature von Willebrand factor.

Authors:  A Leyte; J Voorberg; H B Van Schijndel; B Duim; H Pannekoek; J A Van Mourik
Journal:  Biochem J       Date:  1991-02-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.